Lecture: Shifting gears in CVD & T2DM: What is the rationale for new diabetes interventions in the course of CVD?

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Two choices of drugs that reduce CV risk in T2DM
Two choices of drugs that reduce CV risk in T2DM
CDMC 2018: Shifting gears in the management of diabetes and CVD
Two choices of drugs that reduce CV risk in T2DM
- Prof. John Deanfield, MD
Lecture: Screening for Diabetes: When is it meaningful and how should it be performed
Lecture: Screening for Diabetes: When is it meaningful and how should it be performed
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: Screening for Diabetes: When is it meaningful and how should it be performed
- Prof. Lars Rydén
Lecture: The clinical landscape for T2DM and CVD: impact on guidelines and practice
Lecture: The clinical landscape for T2DM and CVD: impact on guidelines and practice
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: The clinical landscape for T2DM and CVD: impact on guidelines and practice
- Prof John E Deanfield
Lecture: Clinical trials in T2DM & CVD: Review of key outcomes with GLP-1 RA and SGLT2i
Lecture: Clinical trials in T2DM & CVD: Review of key outcomes with GLP-1 RA and SGLT2i
CDMC 2018: Shifting gears in the management of diabetes and CVD
Lecture: Clinical trials in T2DM & CVD: Review of key outcomes with GLP-1 RA and SGLT2i
- Prof. Eduard Montanya Barcelona